U.S. markets closed

BioSyent Inc. (BIOYF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.350.00 (0.00%)
At close: 1:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.35
Open6.35
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.35 - 6.35
52 Week Range3.57 - 6.63
Volume2,579
Avg. Volume4,323
Market Cap81.414M
Beta (5Y Monthly)1.02
PE Ratio (TTM)25.10
EPS (TTM)0.25
Earnings DateAug 24, 2021 - Aug 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • FAX Capital Announces Investment in BioSyent Inc., Files Early Warning Report
    GlobeNewswire

    FAX Capital Announces Investment in BioSyent Inc., Files Early Warning Report

    NOT FOR DISSEMINATION IN THE UNITED STATES OR DISTRIBUTION TO U.S. NEWS WIRE SERVICES TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- FAX Capital Corp. (FAX or the Company) (TSX: FXC & FXC.WT) is pleased to announce that it has acquired ownership of 902,000 common shares (the Shares) of BioSyent Inc. (BioSyent) (TSXV: RX) through the facilities of the Neo Exchange Inc. (the Acquisition). The Shares were acquired at an average price of $7.50 per Share and an aggregate purchase price of $6,765,000. Imm

  • BioSyent Releases Financial Results for Q1 2021
    GlobeNewswire

    BioSyent Releases Financial Results for Q1 2021

    MISSISSAUGA, Ontario, May 27, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2021. Key highlights include: Record first quarter (Q1) 2021 Net Revenues of $7,419,889 increased by 22% versus Q1 2020Q1 2021 Canadian Pharmaceutical Net Revenues of $6,233,763 increased by 5% versus Q1 2020Q1 2021 International Pharmaceutical Net Revenues of $1,140,279 increased by 1,578% versus Q1 2020Q1 2021 EBITDA1 of $2,359,085 increased by 18% versus Q1 2020Q1 2021 EBITDA percentage to Net Revenues of 32% compares to 33% in Q1 2020Q1 2021 Net Income After Taxes (NIAT) of $1,664,368 increased by 15% versus Q1 2020Q1 2021 NIAT percentage to Net Revenues of 22% compares to 24% in Q1 2020Q1 2021 Fully Diluted EPS of $0.13 was $0.02 higher than Q1 2020 Fully Diluted EPS of $0.11Fully Diluted EPS for the Trailing Twelve Months ended March 31, 2021 was $0.31 as compared to $0.35 for the Trailing Twelve Months ended March 31, 2020As at March 31, 2021, the Company had cash, cash equivalents, and short term investments totalling $24,024,252 as compared to $25,577,706 as at December 31, 2020 – a 6% decreaseTotal Shareholders’ Equity increased by 4% to $27,748,707 at March 31, 2021 from $26,795,956 at December 31, 2020Return on Equity for the Trailing Twelve Months ended March 31, 2021 was 15% as compared to 19% for the Trailing Twelve Months ended March 31, 2020During Q1 2021, repurchased and cancelled a total of 74,500 common shares under a Normal Course Issuer Bid (NCIB) “We recorded double-digit sales growth overall in Q1 2021 thanks to continued growth in our Canadian pharmaceutical business and the shipment during the quarter of our largest single international pharmaceutical order to date,” commented Mr. René Goehrum, President and CEO of BioSyent. “Due in part to the incremental sales generated by our new products Tibella® and Combogesic®, our Canadian pharmaceutical business delivered 5% growth against a particularly strong Q1 2020 during which we experienced a short-term surge in demand for certain products at the outset of the COVID-19 pandemic in Canada. For reference, in Q1 2020 our Canadian pharmaceutical business showed 39% revenue growth versus the comparable quarter in the prior year. Our Canadian pharmaceutical business has shown remarkable resilience over the last year operating in a COVID-19 environment. Q1 2021 marked our 43rd consecutive profitable quarter, with a 22% net profit margin, even as we continued to invest in our launch-stage products. As we look to emerge from the third wave of COVID-19 in Canada, we hope to have improved access to our customers moving forward.” The CEO’s presentation on the Q1 2021 Results is available at the following link: www.biosyent.com/q1-21/. The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2021 and 2020 will be posted on www.sedar.com on May 27, 2021. Q1 2021 Interim Financial Statements PDF available at: http://ml.globenewswire.com/Resource/Download/5be8c629-c858-4327-9f4f-ef92bc648df1 Q1 2021 MD&A PDF available at: http://ml.globenewswire.com/Resource/Download/b090185f-4c00-4cd9-b302-d6fef42e01c7 For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 12,702,375 common shares outstanding. BioSyent Inc.Interim Unaudited Condensed Consolidated Statements of Comprehensive Income In Canadian DollarsQ1 2021 Q1 2020 % Change Net Revenues7,419,889 6,062,846 22%Cost of Goods Sold1,563,894 1,261,103 24%Gross Profit5,855,995 4,801,743 22%Operating Expenses and Finance Income/Costs3,602,281 2,866,385 26%Net Income Before Tax2,253,714 1,935,358 16%Tax (including Deferred Tax)589,346 483,840 22%Net Income After Tax1,664,368 1,451,518 15%Net Income After Tax % to Net Revenues22%24% EBITDA2,359,085 1,997,987 18%EBITDA % to Net Revenues32%33% EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization. BioSyent Inc.Interim Unaudited Condensed Consolidated Statements of Financial Position AS ATMarch 31, 2021December 31, 2020% ChangeASSETS Cash, cash equivalents and short term investments$24,024,252$25,577,706-6%Trade and other receivables 2,393,207 1,815,01532%Inventory 2,706,144 2,073,56131%Prepaid expenses and deposits 426,816 307,599100%CURRENT ASSETS 29,550,419 29,773,881-1% Property and equipment 2,090,447 2,161,698-3%Intangible assets 965,319 1,007,822-4%Loans receivable 598,805 597,3320%Deferred tax asset 45,445 30,48149%TOTAL NON CURRENT ASSETS 3,700,016 3,797,333-3%TOTAL ASSETS$33,250,435$33,571,214-1% LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES$3,892,157$5,138,674-24%NON CURRENT LIABILITIES 1,609,571 1,636,584-2%Long term debt - -0%Total Equity 27,748,707 26,795,9564%TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$33,250,435$33,571,214-1% For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web: www.biosyent.com This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

  • BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021
    GlobeNewswire

    BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021

    MISSISSAUGA, Ontario, May 20, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2021 on Thursday, May 27, 2021 at 8:00am EDT. A presentation on the Company’s first quarter 2021 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 12,702,375 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com. For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web: www.biosyent.com